CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
2024年9月11日 - 2:09AM
In a release issued under the same headline earlier today by
Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of
visceral adipose tissue (VAT) at Week 48 has been corrected from
25.6% to 28.3% and the reduction of subcutaneous adipose tissue has
been corrected from 20.1% to 19.5%. The revised release follows:
Lean Loss Ratio of only 21.9%, representing
class-leading preservation of lean mass
Maintenance of lean mass preservation in
individuals over the age of 60, a population at risk for
frailty-related falls and fractures
Visceral adipose tissue (VAT), a risk factor for
cardiovascular disease, reduced by 28.3% at Week 48
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage
biopharmaceutical company, today presented data from its Phase 2,
MRI-based body composition sub-study of pemvidutide in subjects
with overweight and obesity at the 60th Annual Meeting of
the European Association for the Study of Diabetes
(EASD) in Madrid, Spain. Pemvidutide is a novel,
investigational, peptide-based GLP-1/glucagon dual receptor agonist
in development for the treatment of obesity and metabolic
dysfunction-associated steatohepatitis (MASH).
In an MRI sub-study of 67 subjects from the
Phase 2 MOMENTUM obesity trial, 50 of whom were treated with
pemvidutide for 48 weeks, the lean loss ratio, defined as the
change in lean mass compared to the change in total mass, was
21.9%. Lean mass preservation was greater in subjects aged 60 years
and older, in whom the lean loss ratio was only 19.9%. In addition
to lean mass preservation, there was a preferential reduction of
VAT, the adipose tissue associated with cardiovascular risk. At the
2.4mg dose of pemvidutide, VAT was reduced by 28.3% at Week 48
compared to a 19.5% loss in subcutaneous adipose tissue.
“Preservation of lean mass may reduce risk of
falls and fractures, development of co-morbidities, and rates of
all-cause mortality, particularly in individuals over the age of
60,” said Scott Harris, M.D., Chief Medical Officer of Altimmune.
“Given the breadth and diversity of the obesity patient population,
there has been growing attention given to the quality of weight
loss. Our data demonstrates pemvidutide’s class-leading lean mass
preservation, superior to that reported historically with diet and
exercise. The robust reductions in VAT would also be expected to be
associated with a lower risk of cardiovascular disease.”
About PemvidutidePemvidutide is
a novel, investigational, peptide-based GLP-1/glucagon dual
receptor agonist in development for the treatment of obesity and
MASH. Activation of the GLP-1 and glucagon receptors is believed to
mimic the complementary effects of diet and exercise on weight
loss, with GLP-1 suppressing appetite and glucagon increasing
energy expenditure. Glucagon is also recognized as having direct
effects on hepatic fat metabolism, which is believed to lead to
rapid reductions in levels of liver fat and serum lipids. In
clinical trials to date, once-weekly pemvidutide has demonstrated
compelling weight loss, robust reductions in triglycerides, LDL
cholesterol, liver fat content and blood pressure. The U.S. FDA has
granted Fast Track designation to pemvidutide for the treatment of
MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity
trial and is being studied in the ongoing IMPACT Phase 2b MASH
trial.
About AltimmuneAltimmune is a
clinical-stage biopharmaceutical company focused on developing
innovative next-generation peptide-based therapeutics. The Company
is developing pemvidutide, a GLP-1/glucagon dual receptor agonist
for the treatment of obesity and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Forward-Looking StatementAny
statements made in this press release relating to future financial
or business performance, conditions, plans, prospects, trends, or
strategies and other financial and business matters, including
without limitation, the timing of key milestones for our clinical
assets, and the prospects for the utility of, regulatory approval,
commercializing or selling any product or drug candidates, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. In addition, when or if
used in this press release, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they
relate to Altimmune, Inc. may identify forward-looking statements.
The Company cautions that these forward-looking statements are
subject to numerous assumptions, risks, and uncertainties, which
change over time. Important factors that may cause actual results
to differ materially from the results discussed in the forward
looking statements or historical experience include risks and
uncertainties, including risks relating to: delays in regulatory
review, manufacturing and supply chain interruptions, access to
clinical sites, enrollment, adverse effects on healthcare systems
and disruption of the global economy; the reliability of the
results of studies relating to human safety and possible adverse
effects resulting from the administration of the Company’s product
candidates; the Company’s ability to manufacture clinical trial
materials on the timelines anticipated; and the success of future
product advancements, including the success of future clinical
trials. Further information on the factors and risks that could
affect the Company's business, financial conditions and results of
operations are contained in the Company’s filings with the U.S.
Securities and Exchange Commission, including under the heading
“Risk Factors” in the Company’s most recent annual report on Form
10-K and our other filings with the SEC, which are available at
www.sec.gov.
Company Contact:Vipin GargPresident and Chief
Executive OfficerPhone: 240-654-1450ir@altimmune.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
This press release was published by a CLEAR® Verified
individual.
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 9 2024 まで 10 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 10 2023 まで 10 2024